Eagle Pharmaceuticals, Inc. (EGRX) Ownership
EGRX ownership summary
as of October 21, 2026- Institutions
- 43.3% of shares outstanding
- Insiders
- 0.00% of shares outstanding
- Shares outstanding
- 13.2M
- Float
- 7.4M shares available to trade
- Short interest
- 4.44% 351K shares short
- Days to cover
- 4.07 short interest down 17.3% vs prior month
- Institutions 43.35%
- Other investors 56.65%
EGRX top institutional holders
2 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Stanley-Laman Group Ltd | 0.09% | 12K | $47,220 | — | March 31, 2026 |
| 2 | Archer Investment Corporation | <0.01% | 350 | $1,377 | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 2, 0 holders added 0 shares and 0 cut 0.
EGRX top mutual fund and ETF holders
4 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BSF Systematic US Eq Abs Ret A2 USD | 0.43% | 57K | $224,645 | −1,300 (−2.2%) | December 31, 2025 |
| 2 | BlackRock Diversified Equity Alpha Inst | 0.02% | 2,310 | $9,090 | — | June 30, 2026 |
| 3 | Diversified Equity Alpha Fund F | <0.01% | 221 | $870 | −1 (−0.5%) | June 30, 2026 |
| 4 | BlackRock LifePath Dynamic 2040 Fund T | 0.00% | 4 | $16 | +4 (0.0%) | March 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
EGRX insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-01 | Scott Tarriff | Sell | $13.82 | 10,925 | $150,984 |
| 2023-10-02 | Scott Tarriff | Sell | $15.23 | 9,511 | $144,853 |
| 2023-05-15 | Scott Tarriff | Sell | $21.07 | 15,000 | $316,050 |
| 2023-05-11 | Scott Tarriff | Sell | $20.71 | 15,000 | $310,650 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
EGRX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns EGRX
Institutional investors own 43.3% of Eagle Pharmaceuticals's shares and insiders 0.00%. The largest holder is Stanley-Laman Group Ltd with 0.09% of the shares (12K), as of March 31, 2026. Among the top 2 institutions, 0 added shares and 0 reduced their stake in the latest filings. Short interest is 4.44% of the float, or 4.07 days of average trading volume. The share count rose 24.5% since 2012.
Related: EGRX analyst forecast, EGRX key metrics. See the EGRX stock overview for the latest quote and news.
EGRX ownership FAQ
Who owns the most Eagle Pharmaceuticals stock?
The largest shareholders of Eagle Pharmaceuticals are Stanley-Laman Group Ltd (0.09%), Archer Investment Corporation (<0.01%).
What percentage of Eagle Pharmaceuticals is owned by institutions?
Institutions hold 43.3% of Eagle Pharmaceuticals's shares outstanding; insiders hold 0.00%.
Which funds own Eagle Pharmaceuticals?
The largest fund holders of Eagle Pharmaceuticals are BSF Systematic US Eq Abs Ret A2 USD (0.43%), BlackRock Diversified Equity Alpha Inst (0.02%), Diversified Equity Alpha Fund F (<0.01%), BlackRock LifePath Dynamic 2040 Fund T (0.00%).
What is Eagle Pharmaceuticals's short interest?
351K shares of Eagle Pharmaceuticals were sold short, 4.44% of the float; at the average daily volume it would take 4.07 days to cover.
Are insiders buying or selling Eagle Pharmaceuticals?
Of the latest 4 reported insider transactions in Eagle Pharmaceuticals (since May 11, 2023), 0 were purchases and 4 were sales.
How many shares of Eagle Pharmaceuticals are outstanding?
Eagle Pharmaceuticals has 13.2M shares outstanding, of which 7.4M are in the public float.